Amphastar Pharmaceuticals, Inc.

    Jurisdiction
    United States
    LEI
    54930055TH0ZLSAQMJ38
    ISIN
    US03209R1032 (AMPH)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    51 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €45.38 110.4% undervalued
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. Read full profile

    Fundamentals

    Net revenue
    €614.37M
    Gross margin
    50.0%
    EBIT
    €154.95M
    EBIT margin
    25.2%
    Net income
    €114.90M
    Net margin
    18.7%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €663.42M +8.0% €156.58M +36.3%
    €693.94M +4.6% €170.70M +9.0%
    €678.95M -2.2% €164.62M -3.6%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    Last dividend amount
    $0.30
    Ex date
    Payment date

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Petersen Floyd F. N/A -500 $30.98 -$15.49K
    Petersen Floyd F. N/A -500 $20.83 -$10.42K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 495K $14.35M -31K Sell

    Earnings Calls

    Latest earnings call: May 8, 2024 (Q1 2024)

    Add to watchlist

    Notifications